Prosopagnosia
Introduction of Prosopagnosia
Prosopagnosia can be developed or acquired. Some of the most common causes of acquired prosopagnosia include destructive conditions such as posterior cerebral artery stroke or hematoma. Developmental prosopagnosia (DP) is a cognitive disorder characterized by severe facial recognition defects without any known impairments, neurological diseases, or low-level visual or intellectual impairments. It is estimated that about 2% of adults and children have experienced DP or “face blindness”. This situation can seriously affect daily life, and even produce devastating consequences, such as avoiding social interactions, interpersonal problems, damage to careers, and even depression.
Prosopagnosia is Related to Cortical Damage
Damage to specific areas of the cerebral cortex leads to many high visual processing disorders, which have specific roles in processing certain aspects of vision. Face recognition is supported by the collaboration of multiple facial reaction areas in the brain. A neural model is proposed based on the normal face recognition brain area, the occipital face area (OFA), the fuzzy face area (FFA), and the face-selective posterior superior temporal sulcus (pSTS) are used as the core face network (CFN), and the rest of the face response area serves as an extended surface network (EFN). By exploring the resting functional connection (FC) between the facial response areas of patients with DPs, we found that these interrupted FCs are related to DP's behavioral defects in face recognition.
Fig.1 FMRI diagram of DPs and normal core face network (CFN). (Zhao, 2018)
NMDA Receptor Play a Role in Prosopagnosia
Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is an autoimmune disease that exhibits various neurological symptoms, including behavioral changes, memory deficits, seizures, and static form prosopagnosia. The patient can recognize the form of moving objects, but not the form of stationary objects. NMDA receptor encephalitis involves antibodies against the GluN1 subunit of the NMDA receptor. These antibodies may cause the binding, capping, and cross-connection of NMDA receptors, leading to the internalization of neuronal membrane surface receptors, and the dysfunction of signal transmission mediated by glutamine synapses. Therefore, drug mediated signaling pathways related to NMDA receptors may be available regulatory pathways for the treatment of prosopagnosia.
Fig.2 Cognitive network affected by NMDAR dysfunction. (Dalmau, 2016)
Creative Biolabs has many reliable protein/peptides, neurotransmitter, and antibody products in the field of neuroscience,it may be a useful reagent for your research on prosopagnosia and related neuroencephalitis.
Product Name | Biological Activity | Target | Cat.NO. |
ACBC [NMDA Agonist] | Agonist | NMDA Receptor | MOD2005ZP369 |
Amantadine hydrochloride [NMDA Antagonist] | Antagonist | NMDA Receptor | MOD2005ZP370 |
Mouse Anti-GluN1/NR1 Monoclonal Antibody (NS308-48) | WB / IHC / ICC / IF | GRIN1/NMDAR1 | NAB2007FY693 |
Recombinant Human GRIN1 Protein (N-GST) | ELISA / SDS-PAGE / WB | GRIN1/NMDAR1 | NPR2008PZ1542 |
If you need any customized services or products, please feel free to contact us.
References
- Zhao, Y.; et al. The neural network for face recognition: Insights from an fMRI study on developmental prosopagnosia. NeuroImage. 2018, 169: 151-161.
- Dalmau, J. NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: The 2016 Cotzias Lecture. Neurology. 2016, 87(23): 2471-2482.
- NeuroMab™ Anti-GD2 Antibody(NRZP-1222-ZP767) (Cat#: NRZP-1222-ZP767)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P1683) (Cat#: NRP-0422-P1683)
- NeuroMab™ Anti-Alpha Synuclein Antibody(NRP-0422-P614) (Cat#: NRP-0422-P614)
- NeuroMab™ Anti-ApoC3 BBB Shuttle Antibody(NRZP-1022-ZP3503) (Cat#: NRZP-1022-ZP3503)
- NeuroMab™ Anti-CD20 Antibody(NRP-0422-P1230) (Cat#: NRP-0422-P1230)
- NeuroMab™ Anti-TNFα BBB Shuttle Antibody(NRZP-1022-ZP4105) (Cat#: NRZP-1022-ZP4105)
- iNeuMab™ Anti-F-Spondin/SPON1 Antibody, Clone 3F4 (Cat#: NRZP-0822-ZP4740)
- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- NeuroMab™ Anti-pTau Antibody(NRP-0422-P1719) (Cat#: NRP-0422-P1719)
- NeuroMab™ Anti-FGFR1 Antibody(NRP-0422-P1244) (Cat#: NRP-0422-P1244)
- Rat Muller Cell (Cat#: NCL2110P040)
- Green Fluorescent Tau SH-SY5Y cell Line (Cat#: NCL2110P219)
- Rat Retinal Muller Cell Line, Immortalized (Cat#: NCL-21P6-192)
- Mouse Microglia N9 (Cat#: NCL2110P073)
- Mouse Glioma Cell Line GL261 (Cat#: NCL-2108P28)
- Human Astrocytes (Cat#: NCC20-9PZ01)
- Immortalized Human Cerebral Microvascular Endothelial Cells (Cat#: NCL-2108-P020)
- Human Retinal Epithelial Cell ARPE-19 (Cat#: NCL2110P069)
- Mouse Microglia Cell Line BV-2, Immortalized (Cat#: NCL2110P153)
- Mouse Glioma Cell Line GL261-GFP (Cat#: NCL-2108P04)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- pAAV-syn-jGCaMP8s-WPRE (Cat#: NTA-2106-P063)
- rAAV-E-SARE-Cre-ERT2-PEST-WPRE-hGH polyA (Cat#: NTA-2010-TT342)
- Dextran, Cy5 Labeled, 2000 kDa (Cat#: NRZP-0722-ZP22)
- pAAV-syn-jGCaMP8m-WPRE (Cat#: NTA-2106-P062)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- pAAV-syn-jGCaMP8f-WPRE (Cat#: NTA-2106-P061)
- pAAV-syn-FLEX-jGCaMP8s-WPRE (Cat#: NTA-2106-P066)
- AAV2/9-hEF1a-fDIO-eNpHR 3.0-mCherry-WPRE-pA (Cat#: NTA-2012-ZP78)
- Dextran, NHS Activated, 40 kDa (Cat#: NRZP-0722-ZP124)
- pAAV-syn-FLEX-jGCaMP8f-WPRE (Cat#: NTA-2106-P064)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)